Viral Safety Expert, Audrey Brussel, joins PathoQuest
PARIS, FRANCE – December 10, 2020 – PathoQuest, a leader in quality control testing solutions for biologics using advanced sequencing technologies and proprietary databases, today announces the appointment of Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader. Her addition to the company will strengthen PathoQuest’s in-house expertise in viral safety. Her insights and knowledge of the pharmaceutical industry from a customer’s perspective will help deliver a better service and support the growth of the company’s rapidly expanding quality control testing business for biologics.
In her role as Viral Safety Leader, Audrey’s 20 years of experience and expertise within the pharmaceutical industry will contribute to the rapid expansion of PathoQuest’s NGS-based testing solutions which are intended to complement or replace traditional viral safety tests. Her responsibilities will include raising global awareness and accelerating the adoption of NGS as a more effective approach for viral safety testing while also reinforcing PathoQuest’s internal expertise in the field.
Before joining PathoQuest, Audrey was Project Leader for the Corporate Biological Safety Unit of LFB where she was responsible for promoting operational excellence and continuous improvement in pathogen safety. Before this, she worked at Sanofi where she defined policies and led the implementation of best practices related to viral safety during the drug development process and manufacturing for the company’s products. Of note was her role in leading efforts for the evaluation of NGS and media treatment options. Audrey was also an author or reviewer for sections of regulatory dossiers focusing on viral safety tests. While at both Sanofi and LFB, she was a company representative to the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) and was also a member of CAACB’s Steering Committee when she was at LFB. Previous to the above, she was a viral clearance study director at Texcell, a French CRO specialized in viral safety. Audrey received her Ph.D. in Virology and Genetics from the Paris VI University and was a virology post-doctoral fellow at Institut Pasteur.
“PathoQuest offers advanced new options for quality control testing of biological drugs which can reduce the time to market for innovative drugs. I am very excited to take on this challenge alongside PathoQuest’s seasoned team,” stated Audrey Brussel. “I will bring not only my scientific expertise as a virologist but more importantly, my in-depth knowledge of the expectations and constraints of the pharmaceutical industry in a rapidly changing regulatory environment. The biopharmaceutical industry is looking for ways to ensure the safety of biologics while accelerating the time to market and using more ethical approaches to do so. Pathoquest’s NGS-based approach is an obvious answer to support their needs.”
“We believe the success of a company relies on its people and Audrey is a great addition to our team,” commented Jean-Francois Brepson, PathoQuest’s CEO. “Her expertise and knowledge of the industry will undoubtedly further advance our NGS-based biologics testing business further.”
PathoQuest offers biopharmaceutical companies a game-changing genomic approach to ensuring the biosafety of biologics like cell & gene therapy products, vaccines, and recombinant drugs. It also enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences database.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic blood-based test (iDTECT®) designed to improve the diagnosis of bloodstream infections and fight against antimicrobial resistance (AMR).